West Pharmaceutical Services, I which can be found using ticker (WST) now have 9 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price High/Low ranges between 449 and 290 and has a mean target at $369.22. Given that the stocks previous close was at $361.24 this now indicates there is a potential upside of 2.2%. The 50 day moving average now sits at $338.33 and the 200 day moving average is $284.68. The market capitalization for the company is $27,192m. Find out more information at: https://www.westpharma.com
The potential market cap would be $27,793m based on the market consensus.
West Pharmaceutical Services designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
The company has a dividend yield of 0.21% with the ex dividend date set at 25-7-2023 (DMY).
Other points of data to note are a P/E ratio of 50.22, revenue per share of 38.74 and a 13.22% return on assets.
